Efficiency and safety of percutaneous ultrasound-guided radiofrequency ablation for right adrenal metastases from hepatocellular carcinoma
10.3760/cma.j.issn.1004-4477.2020.02.009
- VernacularTitle:超声引导下经皮射频消融治疗肝细胞癌肾上腺转移瘤的安全性及疗效评估
- Author:
Baoxian LIU
1
;
Yangyang LEI
;
Yang TAN
;
Xiaohua XIE
;
Jingzhi HUANG
;
Xiaoyan XIE
Author Information
1. 中山大学第一附属医院超声医学科，广州 510080
- From:
Chinese Journal of Ultrasonography
2020;29(2):149-152
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To retrospectively summarize and evaluate the efficiency and safety of percutaneous ultrasound-guided radiofrequency ablation (RFA) for adrenal metastasis (AM) from hepatocellular carcinoma (HCC).Methods:From October 2009 to September 2018, 16 patients with AM from HCC who underwent percutaneous RFA in the First Affiliated Hospital of Sun Yat-Sen University were enrolled in the study. The complete ablation and local tumor progression rates were elevated, and the side effects and complications were summarized.Results:The median ablation time of AM was 16 min. The complete ablation rate was 87.5% (14/16). After the follow-up period of 3 to 55 months, among the patients with complete ablation, there were 3 patients were detected local tumor progression (LTP), the LTP rate was 21.4% (3/14). As for the side effects and complications, 3 patients were diagnosed as hypertension crisis (3/16, 18.8%), 2 showed reduced heart rate and 1 of them exhibited frequent premature ventricular contraction which resulted in termination of ablation. There was no ablation-related death or adrenal failure.Conclusions:Percutaneous US-guided RFA is safe and effective in the treatment of AM originated from HCC.
